EurekaMag
+ Translate
+ Most Popular
Advantages and disadvantages of bordeaux mixture and of lime-sulphur used on apples in the growing season
Observations on the Umaria marine bed
10 years of hearing conservation in the Royal Air Force
Chocolate crumb - dairy ingredient for milk chocolate
Effect of daily gelatin ingestion on human scalp hair
Comparison of rice bran and maize bran as feeds for growing and fattening pigs
The composition of pampas-grass (Cortaderia argentea.)
The Accraian Series:
The mechanism of the Liebermann-Burchard reaction of sterols and triterpenes and their esters
Cerebrovascular Doppler ultrasound studies (cv-Doppler)
Toria: PT-303 - first national variety
Hair growth promoting activity of tridax procumbens
Productivity of Pekin x Khaki Campbell ducks
A stable cytosolic expression of VH antibody fragment directed against PVY NIa protein in transgenic potato plant confers partial protection against the virus
Solar treatment of wheat loose smut
Swimmers itch in the Lake of Garda
Bactofugation and the Bactotherm process
The effects of prefrontal lobotomy on aggressive behavior in dogs
Visual rating scales for screening whorl-stage corn for resistance to fall armyworm
Breakdown of seamounts at the trench axis, viewed from gravity anomaly
Kooken; pennsylvania's toughest cave
Recovery of new dinosaur and other fossils from the Early Cretaceous Arundel Clay facies (Potomac Group) of central Maryland, U.S.A
Zubor horny (Bison bonasus) v prirodnych podmienkach Slovensku
The extended Widal test in the diagnosis of fevers due to Salmonella infection
Hair of the american mastodon indicates an adaptation to a semi aquatic habitat

Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia


Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia



Atherosclerosis 63(1): 57-64



ISSN/ISBN: 0021-9150

PMID: 3548734

DOI: 10.1016/0021-9150(87)90082-7

The effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia were assessed in a 6-month parallel group study, placebo (n=15) versus fenofibrate 300 mg/day (n=18), followed by an open label 6-month treatment period. After stabilization on an isocaloric low fat (<35% total calories) diet with <250 mg cholesterol/day and a P/S ratio of 1, and maintenance of LDL-cholesterol (LDL-C) levels .gtoreq. 175 mg/dl, subjects received placebo for 6 weeks and were then randomized into placebo or fenofibrate groups for 6 months, followed by open label treatment for 6 months. During the 6-month double-blind period, compared to the placebo group, the treatment group had significant reductions in total cholesterol, LDL-C, total apo B, and triglyceride, and increments in HDL-cholesterol, apolipoprotein A-I and apolipoprotien A-II (P < 0.01 for all comparisons). Compared to placebo baseline, therapy with fenofibrate resulted in a reduction of LDL-C, apo B, and the LDL-C/HDL-C ratio of 15%, 13%, and 18% respectively; HDL-C, Apo A-I, and apo A-II increased respectively 12%, 13% and 30% (P < 0.01 for all comparisons). Mean adherence during the double blind phase of the trial was 95% in the drug group and 96% in the placebo group. An additional 6 months of open label fenofibrate therapy maintained the reduced total and LDL-C as well as the elevated HDL-C, apo A-I and apo A-II in the drug-drug group. Similar lipid, lipoprotein, and apolipoprotein changes were achieved in the placebo-drug group, so that the two sequence groups did not differ at the end of 6 months of open label therapy, P > 0.1. In subjects with primary hypercholesterolemia, fenofibrate, in conjunction with diet, effectively lowered LDL-C, apo B, and triglycerides, and increased HDL-C, apo A-I, and apo A-II. These effects, combined with its ease of administration and lack of side effects, enhance fenofibrate's importance and utility as a pharmacologic agent in the treatment of hypercholesterolemic subjects.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 005304062

Download citation: RISBibTeXText

Related references

Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia. European Journal of Clinical Pharmacology 37(2): 199-203, 1989

Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia. Minerva Cardioangiologica 37(12): 509-515, 1989

Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia. European Journal of Clinical Pharmacology 30(2): 191-194, 1986

Dependent oedema and attenuation of postural vasoconstriction associated with nifedipine therapy for hypertension in diabetic patients. European Journal of Clinical Pharmacology 37(4): 333-335, 1989

Effects of polydextrose on serum lipids, lipoproteins, and apolipoproteins in healthy subjects. Clinical Therapeutics 13(2): 254-258, 1991

Effects of simvastatin on plasma lipids and apolipoproteins in primary hypercholesterolemia. Gotto, A M Jr , Et Al (Ed ) Treatment Of Severe Hypercholesterolemia in The Prevention Of Coronary Heart Disease; 2nd International Symposium, Munich, West Germany, June 29-30, 1989 Ix+274p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 112-115, 1990

Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia. La Clinica Terapeutica 122(1): 17-23, 1987

A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism: Clinical and Experimental 41(5): 498-503, 1992

Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia. Clinical Therapeutics 11(2): 247-257, 1989

Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. Canadian Journal of Cardiology 7(1): 27-33, 1991

n-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects. American Journal of Clinical Nutrition 51(4): 599-605, 1990

N-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects. The American Journal of Clinical Nutrition 51(4): 599-605, 1990

Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia. Atherosclerosis 53(3): 321-325, 1984

Effect of therapy on blood serum lipids and prolonged fenofibrate lipoproteins in patients with hypercholesterolemia and hypertriglyceridemia. Polski Tygodnik Lekarski 41(51-52): 1633-1637, 1986

Effect of long-term treatment with fenofibrate on serum lipids and lipoproteins in patients with hypercholesterolemia and hypertriglyceridemia. Polski Tygodnik Lekarski 41(51-52): 1633-1637, 1986